Ciclesonide
- Generic Name
- Ciclesonide
- Brand Names
- Alvesco, Omnaris, Zetonna
- Drug Type
- Small Molecule
- Chemical Formula
- C32H44O7
- CAS Number
- 126544-47-6
- Unique Ingredient Identifier
- S59502J185
- Background
Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
- Indication
For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
- Associated Conditions
- Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers
- Conditions
- Healthy
- Interventions
- Drug: BI 54903 XX highDrug: BI 54903 XX medium 2Drug: BI 54903 XX lowDrug: BI 54903 XX medium 1
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT02221375
Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT02155881
A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- First Posted Date
- 2012-07-31
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 737
- Registration Number
- NCT01654536
- Locations
- 🇺🇸
Kerrville Research Associates, PA, Kerrville, Texas, United States
🇺🇸Clinical Research Group of Montanta, Bozeman, Montana, United States
🇺🇸Valley Clinical Research Center, Bethlehem, Pennsylvania, United States
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 847
- Registration Number
- NCT01458275
- Locations
- 🇺🇸
Dallas Allergy Immunology Research, Dallas, Texas, United States
🇺🇸Kerrville Research Associates, Kerrville, Texas, United States
🇺🇸San Jose Multispecialty Medical Group, Inc, Baldwin Park, California, United States
Effect of High Dose Ciclesonide on Asthma Control
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 520
- Registration Number
- NCT01455194
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).
- Conditions
- Perennial Allergic RhinitisPAR
- Interventions
- First Posted Date
- 2011-10-13
- Last Posted Date
- 2014-05-06
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 848
- Registration Number
- NCT01451541
- Locations
- 🇺🇸
Sansum Clinic, Santa Barbara, California, United States
🇺🇸West Coast Clinical Trials, LLC, Costa Mesa, California, United States
🇺🇸National Allergy, Ashtma, and Urticaria Centers of Charleston, PA, North Charleston, South Carolina, United States
Omnaris Versus Levocetirizine Phase 4 Study
- Conditions
- Allergic Rhinitis
- Interventions
- First Posted Date
- 2011-09-08
- Last Posted Date
- 2012-09-06
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 349
- Registration Number
- NCT01430260
- Locations
- 🇰🇷
handok pharmaceuticals co. LTD, Seoul, Korea, Republic of
Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray
- First Posted Date
- 2011-07-25
- Last Posted Date
- 2013-04-30
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 327
- Registration Number
- NCT01401465
- Locations
- 🇺🇸
The Clinical Research Center, L.L.C., St. Louis, Missouri, United States
🇺🇸Clinical Research Institute of Southern Oregon, PC, Medford, Oregon, United States
🇺🇸Pharmacuetical Research & Consulting, Inc., Dallas, Texas, United States
Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis
- Conditions
- PARPerennial Allergic Rhinitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-06-22
- Last Posted Date
- 2014-05-26
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT01378429
- Locations
- 🇺🇸
Sneeze, Wheeze, & Itch Associates, LLC, Normal, Illinois, United States
🇺🇸West Coast Clinical Trials, Costa Mesa, California, United States
🇺🇸Clinical Research Atlanta, Stockbridge, Georgia, United States
A Phase 1 Scintigraphy Study to Assess Nasal Deposition of Ciclesonide. Using a Novel Nasal Metered Dose Inhaler
- Conditions
- Allergic Rhinitis (AR)
- Interventions
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT01371786
- Locations
- 🇬🇧
Quotient Clinical, Ruddington Fields, Ruddington, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.